{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:49:20Z","timestamp":1789804160078,"version":"4.0.1"},"reference-count":64,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EB023776"],"award-info":[{"award-number":["R01EB023776"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>This review discusses current bottlenecks in making CRISPR-Cas9-mediated genome editing a therapeutic reality and it outlines recent strategies that aim to overcome these hurdles as well as the scope of current clinical trials that pioneer the medical translation of CRISPR-Cas9. Additionally, this review outlines the specifics of disease-modifying gene editing in recessive versus dominant genetic diseases with the focus on genetic myopathies that are exemplified by Duchenne muscular dystrophy and myotonic dystrophies.<\/ns4:p>","DOI":"10.12688\/f1000research.16106.1","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T07:12:17Z","timestamp":1545376337000},"page":"1970","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Making gene editing a therapeutic reality"],"prefix":"10.12688","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4276-0644","authenticated-orcid":false,"given":"Irina","family":"Conboy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niren","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2173-6191","authenticated-orcid":false,"given":"Jessy","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachery","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"443-68","DOI":"10.3892\/ijo.2018.4434","article-title":"CRISPR therapeutic tools for complex genetic disorders and cancer (Review).","volume":"53","author":"S Baliou","year":"2018","journal-title":"Int J Oncol."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting Hepatitis B Virus With CRISPR\/Cas9.","volume":"3","author":"C Seeger","year":"2014","journal-title":"Mol Ther Nucleic Acids."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"167-72","DOI":"10.24875\/AIDSRev.M17000008","article-title":"Hot News: Gene Therapy with CRISPR\/Cas9 Coming to Age for HIV Cure.","volume":"19","author":"V Soriano","year":"2017","journal-title":"AIDS Rev."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"1-9","DOI":"10.1038\/ncb3452","article-title":"The control of DNA repair by the cell cycle.","volume":"19","author":"N Hustedt","year":"2016","journal-title":"Nat Cell Biol."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"497-510","DOI":"10.1016\/j.molcel.2012.07.029","article-title":"Playing the end game: DNA double-strand break repair pathway choice.","volume":"47","author":"J Chapman","year":"2012","journal-title":"Mol Cell."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9.","volume":"346","author":"J Doudna","year":"2014","journal-title":"Science."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"704-12","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.","volume":"21","author":"S Boutin","year":"2010","journal-title":"Hum Gene Ther."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"417-24","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.","volume":"20","author":"F Mingozzi","year":"2013","journal-title":"Gene Ther."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"119-29","DOI":"10.1016\/j.omtm.2018.02.003","article-title":"Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.","volume":"9","author":"Z Fitzpatrick","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"243-51","DOI":"10.2174\/1574888X13666180214124800","article-title":"CRISPR\/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.","volume":"13","author":"Y Zhang","year":"2018","journal-title":"Curr Stem Cell Res Ther."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"765-71","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements.","volume":"36","author":"M Kosicki","year":"2018","journal-title":"Nat Biotechnol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"1241-54","DOI":"10.1016\/j.ymthe.2018.02.023","article-title":"Efficient In Vivo Liver-Directed Gene Editing Using CRISPR\/Cas9.","volume":"26","author":"K Singh","year":"2018","journal-title":"Mol Ther."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"939-46","DOI":"10.1038\/s41591-018-0050-6","article-title":"p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.","volume":"24","author":"R Ihry","year":"2018","journal-title":"Nat Med."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"927-30","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response.","volume":"24","author":"E Haapaniemi","year":"2018","journal-title":"Nat Med."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"208-25","DOI":"10.1111\/bjh.14297","article-title":"CRISPR-Cas9 technology and its application in haematological disorders.","volume":"175","author":"H Zhang","year":"2016","journal-title":"Br J Haematol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fcell.2018.00046","article-title":"Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases.","volume":"6","author":"C Xu","year":"2018","journal-title":"Front Cell Dev Biol."},{"key":"ref-17","article-title":"CRISPR trials are about to begin in people\u2014but we still don\u2019t know how well it works in monkeys","author":"E Mullin","year":"2018"},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nature.2016.20988","article-title":"CRISPR gene-editing tested in a person for the first time.","volume":"539","author":"D Cyranoski","year":"2016","journal-title":"Nature."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"309-19","DOI":"10.2174\/1566523217666171121165935","article-title":"First-in-human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?","volume":"17","author":"F Baylis","year":"2017","journal-title":"Curr Gene Ther."},{"key":"ref-20","article-title":"FDA Puts Clinical Trial for CRISPR Therapy on Hold","author":"A Burik","year":"2018"},{"key":"ref-21","article-title":"The FDA Has Just Put The Brakes on a Major CRISPR Trial in Humans","author":"K Houser","year":"2018"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"14457-67","DOI":"10.1074\/jbc.M116.733154","article-title":"Highly Efficient Mouse Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes.","volume":"291","author":"S Chen","year":"2016","journal-title":"J Biol Chem."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"407-11","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells.","volume":"351","author":"M Tabebordbar","year":"2016","journal-title":"Science."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"403-7","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.","volume":"351","author":"C Nelson","year":"2016","journal-title":"Science."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"400-3","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy.","volume":"351","author":"C Long","year":"2016","journal-title":"Science."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"1059-71","DOI":"10.1016\/j.cell.2010.11.039","article-title":"Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx\/mTR mice.","volume":"143","author":"A Sacco","year":"2010","journal-title":"Cell."},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1038\/npjregenmed.2016.6","article-title":"Targeting muscle stem cell intrinsic defects to treat Duchenne muscular dystrophy.","volume":"1","author":"N Dumont","year":"2016","journal-title":"NPJ Regen Med."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"889-901","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair.","volume":"1","author":"K Lee","year":"2017","journal-title":"Nat Biomed Eng."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"199-207","DOI":"10.1007\/s11926-011-0178-6","article-title":"The muscular dystrophies: distinct pathogenic mechanisms invite novel therapeutic approaches.","volume":"13","author":"Z Sahenk","year":"2011","journal-title":"Curr Rheumatol Rep."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"1023-31","DOI":"10.1161\/01.RES.0000126574.61061.25","article-title":"The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma.","volume":"94","author":"K Lapidos","year":"2004","journal-title":"Circ Res."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"253-305","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.","volume":"96","author":"D Allen","year":"2016","journal-title":"Physiol Rev."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"1223-39","DOI":"10.1002\/cphy.c140048","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy.","volume":"5","author":"Q Gao","year":"2015","journal-title":"Compr Physiol."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1121-31","DOI":"10.1016\/0092-8674(91)90035-W","article-title":"Membrane organization of the dystrophin-glycoprotein complex.","volume":"66","author":"J Ervasti","year":"1991","journal-title":"Cell."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"1-3","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.","volume":"27","author":"A Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref-35","article-title":"Positive Trial Results for Experimental DMD Gene Therapy","author":"C Offord","year":"2018"},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"533-40","DOI":"10.1016\/j.stem.2016.01.021","article-title":"A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.","volume":"18","author":"C Young","year":"2016","journal-title":"Cell Stem Cell."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"e72147","DOI":"10.1371\/journal.pone.0072147","article-title":"Revertant fibers in the mdx murine model of Duchenne muscular dystrophy: An age- and muscle-related reappraisal.","volume":"8","author":"S Pigozzo","year":"2013","journal-title":"PLoS One."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-3-16","article-title":"Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.","volume":"3","author":"L Fregonese","year":"2008","journal-title":"Orphanet J Rare Dis."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"71-80","DOI":"10.1165\/rcmb.2015-0154OC","article-title":"Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization.","volume":"54","author":"I Haq","year":"2016","journal-title":"Am J Respir Cell Mol Biol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"1183-90","DOI":"10.1172\/JCI113999","article-title":"Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice.","volume":"83","author":"J Carlson","year":"1989","journal-title":"J Clin Invest."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"853-60","DOI":"10.1089\/hum.2017.225","article-title":"In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency.","volume":"29","author":"C Song","year":"2018","journal-title":"Hum Gene Ther."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"77-90","DOI":"10.2174\/138920210790886844","article-title":"Myotonic dystrophies 1 and 2: Complex diseases with complex mechanisms.","volume":"11","author":"B Schoser","year":"2010","journal-title":"Curr Genomics."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"594-606","DOI":"10.1016\/j.bbadis.2014.05.019","article-title":"Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.","volume":"1852","author":"G Meola","year":"2015","journal-title":"Biochim Biophys Acta."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"24-43","DOI":"10.1016\/j.ymthe.2016.10.014","article-title":"CRISPR\/Cas9-Induced (CTG\u22c5CAG)n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome Editing.","volume":"25","author":"E van Agtmaal","year":"2017","journal-title":"Mol Ther."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"1179-87","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing.","volume":"35","author":"H Yin","year":"2017","journal-title":"Nat Biotechnol."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"73-80","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.","volume":"33","author":"J Zuris","year":"2015","journal-title":"Nat Biotechnol."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"497-507","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours.","volume":"2","author":"B Lee","year":"2018","journal-title":"Nat Biomed Eng."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"12029-33","DOI":"10.1002\/anie.201506030","article-title":"Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing.","volume":"54","author":"W Sun","year":"2015","journal-title":"Angew Chem Int Ed Engl."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"107-119.e6","DOI":"10.1016\/j.stem.2017.06.003","article-title":"Muscle Stem Cells Undergo Extensive Clonal Drift during Tissue Growth via Meox1-Mediated Induction of G2 Cell-Cycle Arrest.","volume":"21","author":"P Nguyen","year":"2017","journal-title":"Cell Stem Cell."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"99-102","DOI":"10.1126\/science.aan8795","article-title":"Cell cycle heterogeneity directs the timing of neural stem cell activation from quiescence.","volume":"360","author":"L Otsuki","year":"2018","journal-title":"Science."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"538-42","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining.","volume":"33","author":"T Maruyama","year":"2015","journal-title":"Nat Biotechnol."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1038\/s41598-017-09306-x","article-title":"Small molecules enhance CRISPR\/Cas9-mediated homology-directed genome editing in primary cells.","volume":"7","author":"G Li","year":"2017","journal-title":"Sci Rep."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"187-201","DOI":"10.1139\/bcb-2016-0137","article-title":"Precision genome editing in the CRISPR era.","volume":"95","author":"J Salsman","year":"2017","journal-title":"Biochem Cell Biol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"43-52","DOI":"10.1016\/j.biocel.2017.09.012","article-title":"Enhancing CRISPR\/Cas9-mediated homology-directed repair in mammalian cells by expressing Saccharomyces cerevisiae Rad52.","volume":"92","author":"S Shao","year":"2017","journal-title":"Int J Biochem Cell Biol."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"E10745-E10754","DOI":"10.1073\/pnas.1711979114","article-title":"Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks.","volume":"114","author":"A Paix","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"e1701620","DOI":"10.1126\/sciadv.1701620","article-title":"Disabling Cas9 by an anti-CRISPR DNA mimic.","volume":"3","author":"J Shin","year":"2017","journal-title":"Sci Adv."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13059-018-1459-4","article-title":"DeepCRISPR: optimized CRISPR guide RNA design by deep learning.","volume":"19","author":"G Chuai","year":"2018","journal-title":"Genome Biol."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"12-21","DOI":"10.1016\/j.tibtech.2016.06.008","article-title":"In Silico Meets In Vivo: Towards Computational CRISPR-Based sgRNA Design.","volume":"35","author":"G Chuai","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"760-72","DOI":"10.1038\/nbt.2989","article-title":"Microfluidic organs-on-chips.","volume":"32","author":"S Bhatia","year":"2014","journal-title":"Nat Biotechnol."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"FSO130","DOI":"10.4155\/fsoa-2016-0038","article-title":"Organ-on-chip models: new opportunities for biomedical research.","volume":"3","author":"A Mosig","year":"2016","journal-title":"Future Sci OA."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"1645-54","DOI":"10.1039\/C6LC01590E","article-title":"WAT-on-a-chip: a physiologically relevant microfluidic system incorporating white adipose tissue.","volume":"17","author":"P Loskill","year":"2017","journal-title":"Lab Chip."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"8883","DOI":"10.1038\/srep08883","article-title":"Human iPSC-based cardiac microphysiological system for drug screening applications.","volume":"5","author":"A Mathur","year":"2015","journal-title":"Sci Rep."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"e0139587","DOI":"10.1371\/journal.pone.0139587","article-title":"\u03bcOrgano: A Lego\u00ae-Like Plug & Play System for Modular Multi-Organ-Chips.","volume":"10","author":"P Loskill","year":"2015","journal-title":"PLoS One."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"86-91","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy.","volume":"362","author":"L Amoasii","year":"2018","journal-title":"Science."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:10:46Z","timestamp":1553861446000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":64,"URL":"https:\/\/doi.org\/10.12688\/f1000research.16106.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.17587.r42192","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.17587.r42193","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.17587.r42192, B\u00e9 Wieringa, Radboud University Medical Center, Department of Cell Biology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands, 21 Dec 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1#referee-response-42192","order":0,"name":"referee-response-42192","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.17587.r42193, Michael Rudnicki, Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, USA, 21 Dec 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1970\/v1#referee-response-42193","order":1,"name":"referee-response-42193","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by National Institutes of Health grant R01 EB023776 and Open Philanthropy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}